The PREDICT Registry:
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age30-85
SponsorPreludeDx
About this trial
This is a prospective, non-interventional (observational) cohort study conducted within the medical network of the participating investigators and institutions. Patients meeting the eligibility criteria (see below) will be eligible for participation and the investigators will obtain written informed consent. A central Institutional Review Board (IRB), WCG IRB, will approve the protocol and each participating institution.
Eligibility criteria
Qualifiers
Patient must have histologically confirmed ductal carcinoma in situ (DCIS) in a single breast (presence of lobular carcinoma in situ (LCIS) or other benign breast disease in addition to DCIS is acceptable).
Patient must have the DCISionRT test ordered during routine patient care.
Patient must be eligible for or have recently completed breast conserving surgery.
Patient must be eligible to receive radiation and/or systemic treatment.
Disqualifiers
Patient tissue is insufficient to generate DCISionRT test results or required DCISionRT inputs (age, tumor size, margin status, palpability) are missing.
Patient has evidence of invasive breast cancer, including microinvasion, lymph node involvement, or Paget's disease of the nipple or suspicious mammogram findings in the lymph nodes or contralateral breast.
Patient has been surgically treated with an ipsilateral mastectomy for primary DCIS.
Patient has had any prior ipsilateral or contralateral breast DCIS or invasive breast cancer.
Trial design
Treatments tested in this trial
- Treatment recommendation surveys
- 7-gene biosignature
Treatment groups
3,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov